1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
    Neuronal Signaling
  3. Calcium Channel
  4. Calcium Channel Isoform
  5. Calcium Channel Antagonist

Calcium Channel Antagonist

Calcium Channel Antagonists (56):

Cat. No. Product Name Effect Purity
  • HY-14275
    Verapamil
    Antagonist 99.96%
    Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor.
  • HY-B0284
    Nifedipine
    Antagonist 99.05%
    Nifedipine (BAY-a-1040) is a potent calcium channel blocker and drug of choice for cardiac insufficiencies.
  • HY-A0064
    Verapamil hydrochloride
    Antagonist 99.98%
    Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor.
  • HY-14656
    Diltiazem hydrochloride
    Antagonist 99.50%
    Diltiazem hydrochloride is a Ca2+ influx inhibitor (slow channel blocker or calcium antagonist).
  • HY-B1077
    Penfluridol
    Antagonist 99.93%
    Penfluridol is a highly potent, first generation diphenylbutylpiperidine antipsychotic.
  • HY-103315
    Bepridil hydrochloride
    Antagonist 99.76%
    Bepridil hydrochloride (CERM 1978) is a calcium channel blocker, with antianginal activity.
  • HY-Z0816
    Dehydronitrosonisoldipine
    Antagonist ≥98.0%
    Dehydronitrosonisoldipine, a derivative of Nisoldipine (HY-17402), is an irreversible and cell-permeant sterile alpha and TIR motif-containing 1 (SARM1) inhibitor.
  • HY-B0317B
    Amlodipine besylate
    Antagonist 99.92%
    Amlodipine besylate (Amlodipine benzenesulfonate), an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium.
  • HY-111828
    TTA-A2
    Antagonist ≥99.0%
    TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation.
  • HY-14284
    Nilvadipine
    Antagonist 99.96%
    Nilvadipine is a potent calcium channel antagonist, and the IC50 value is around 0.1 nM.
  • HY-16952A
    Bepridil hydrochloride hydrate
    Antagonist 99.73%
    Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting Ca+ channel antagonist and Na+, K+ channel inhibitor, with antianginal and type I antiarrhythmic effects.
  • HY-10388
    TTA-Q6
    Antagonist 99.97%
    TTA-Q6 is a selective T-type Ca2+ channel antagonist, which can be used in the research of neurological disease.
  • HY-116408A
    Propiverine hydrochloride
    Antagonist 98.93%
    Propiverine hydrochloride is a bladder spasmolytic with calcium antagonistic and anticholinergic properties.
  • HY-B0549A
    Flavoxate hydrochloride
    Antagonist 99.89%
    Flavoxate hydrochloride is a potent and competitive phosphodiesterase (PDE) inhibitor.
  • HY-108974
    Drotaverine hydrochloride
    Antagonist 99.48%
    Drotaverine (hydrochloride) is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate.
  • HY-B0317A
    Amlodipine maleate
    Antagonist 99.87%
    Amlodipine maleate is a dihydropyridine calcium channel blocker, acts as an orally active antianginal agent.
  • HY-14276A
    Gallopamil hydrochloride
    Antagonist ≥98.0%
    Gallopamil hydrochloride (Methoxyverapamil hydrochloride), a methoxy derivative of Verapamil, is a phenylalkylamine calcium antagonist.
  • HY-U00212
    Aranidipine
    Antagonist 98.67%
    Aranidipine (MPC1304) is a Ca2+ channel antagonist with potent and long-lasting antihypertensive effects.
  • HY-103318
    PD173212
    Antagonist 98.43%
    PD173212 is a selective N-type voltage sensitive calcium channel (VSCC) blocker, with an IC50 of 36 nM in IMR-32 assays.
  • HY-17436
    Clevidipine
    Antagonist 99.88%
    Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension.